Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immunogenicity include dose-intensification and/or the addition of an immunomodulator. However, there is a relative paucity of data on the efficacy of such interventions in pediatric IBD patients. Available reports have not strictly utilized homogenous mobility shift assay, which reports on anti-drug antibodies even in the presence of detectable drug, whereas prior studies have been confounded by the use of drug sensitive assays. We report four pediatric inflammatory bowel disease patients with successful reversal of immunogenicity on an anti-TNF agent using dose intensification and/or addition of an immunomodulator.
Abstract
Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immunogenicity include dose-intensification and/or the addition of an immunomodulator. However, there is a relative paucity of data on the efficacy of such interventions in pediatric IBD patients. Available reports have not strictly utilized homogenous mobility shift assay, which reports on anti-drug antibodies even in the presence of detectable drug, whereas prior studies have been confounded by the use of drug sensitive assays. We report four pediatric inflammatory bowel disease patients with successful reversal of immunogenicity on an anti-TNF agent using dose intensification and/or addition of an immunomodulator.
참고문헌 (19)
- Cuffari C, "Inflammatory bowel disease in the pediatric and adolescent patient", Gastroenterol Clin North Am, 31, pp.275~291 (2002)[DOI]
- Peyrin-Biroulet L, "Review article: remission rates achievable by current therapies for inflammatory bowel disease", Aliment Pharmacol Ther, 33, pp.870~879 (2011)[DOI]
- Hanauer SB, "Maintenance in- fliximab for Crohn's disease: the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)[DOI]
- Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)[DOI]
- Cassinotti A, "Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review", Inflamm Bowel Dis, 15, pp.1264~1275 (2009)[DOI]
- Baert F, "Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease", N Engl J Med, 348, pp.601~608 (2003)[DOI]
- Hindryckx P, "Incidence, prevention and management of anti-drug antibodies against ther- apeutic antibodies in inflammatory bowel disease: a practical overview", Drugs, 77, pp.363~377 (2017)[DOI]
- Minar P, "Practical use of infliximab concentration monitoring in pediatric Crohn disease", J Pediatr Gastroenterol Nutr, 62, pp.715~722 (2016)[DOI]
- Wang SL, "Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum", J Immunol Methods, 382, pp.177~188 (2012)[DOI]
- Gisbert JP, "Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review", Am J Gastroenterol, 104, pp.760~767 (2009)[DOI]
- Baert F, "Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial", Gut, 65, pp.1126~1131 (2016)[DOI]
- Nanda KS, "Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis", Am J Gastroenterol, 108, pp.40~47 (2013)[DOI]
- Vande Casteele N, "Antibody response to infliximab and its impact on pharmacokinetics can be transient", Am J Gastroenterol, 108, pp.962~971 (2013)[DOI]
- Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn's disease", N Engl J Med, 362, pp.1383~1395 (2010)[DOI]
- Panaccione R, "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis", Gastroenterology, 146, pp.392~400 (2014)[DOI]
- Vande Casteele N, "The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease", Gut, 64, pp.1539~1545 (2015)[DOI]
- Feuerstein JD, "American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease", Gastroenterology, 153, pp.827~834 (2017)[DOI]
- Vande Casteele N, "Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease", Gastroenterology, 148, pp.1320~1329 (2015)[DOI]
- Sandborn WJ, "Effects of transient and persistent anti-drug antibodies to certolizuman pegol: longitudinal data from a 7-year study in Crohn's disease", Inflamm Bowel Dis, 23, pp.1047~1056 (2017)[DOI]